Dermal and Pulmonary RNAi / PSR
The RNAi / PSR technology is ideally suited for dermal, pulmonary, and transdermal conditions where localized Antiproliferative, Anti-inflammatory , or Antiviral activity would provide therapeutic benefit. The unique PK and MOA would provide a superior treatment for pulmonary conditions including COPD, Asthma, and Avian Flu, dermal conditions including Psoriasis, Actinic Keratosis, Herpes Lesions, and Acne, and transdermal including Rheumatoid Arthritis and Macular Degeneration (Wet).
• Executive Summary (HTML)
(PDF)
• Comparison of Antisense RNA, siRNA, and RNAi / PSR (HTML)
(PDF)
• Slide Show (PDF)
• Full Product, Clinical, and Patent Data (PDF)
Cancer
Today’s chemotherapy protocols fail to cure the vast majority of cancers. We have identified the reasons for this failure. Our solution to this problem is termed Tumor Specific (TS) Cell Cycle Synchronous Chemotherapy (CCSC). The novel protocols are protected by a series of issued and pending patents. Detailed disclosures are provided in US Patent 7,507,704 (PDF) and in a detailed slide show on Cancer and Chemotherapy. A summary is provided below.
• Executive Summary (HTML)
(PDF)
• TS - CCSC Chemotherapy Protocol Slide Show
• TS - CCSC Full Science and Business Slides (PDF)
Migraines and Seizures
Our latest research has identified a novel etiology underlying migraines and seizures. It finally provides a coherent explanation for all of the disparate symptoms and observations related to most migraines as well as many types of seizures. Accordingly, novel treatment methods are proposed that target the underlying etiology, rather than today’s treatments that target downstream events or symptoms. We currently have patents pending in this area and the website will be updated accordingly.
Contact Info: Mark Zamoyski, e-mail to:mark@nexgen.biz, Tel: 408-365-1170
DISCLAIMER AND IMPORTANT NOTICE:The Compositions and Methods presented on this website are all in preclinical stages. They are based only on our understanding of the proposed underlying mechanisms of action and on any available coincidental corroborative empirical evidence, any of which may in fact turn out not to be correct, or may be prevented from functioning as envisioned because of other factors or mechanisms of action not contemplated or considered, or may even cause harm because of factors or mechanisms of action not anticipated. The process of obtaining FDA approvals has not been started in any of the areas disclosed on this website. The disclosures here are purely for scientific information exchange purposes, representing one scientific point of view, and are not intended to suggest, or be used for, any proposed medical treatments.
© 2002 - 2010 Mark Zamoyski & NexGen Biomedical, Inc.